S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Price, News & Analysis

$1.85
-0.01 (-0.54%)
(As of 03/28/2024 ET)
Today's Range
$1.72
$1.90
50-Day Range
$1.80
$2.70
52-Week Range
$1.66
$5.50
Volume
13,382 shs
Average Volume
13,858 shs
Market Capitalization
$10.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AKTX stock logo

About Akari Therapeutics Stock (NASDAQ:AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Stock Price History

AKTX Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Akari Therapeutics PLC (AKTX)
Akari Therapeutics to Present at Biotech Showcase 2024
Akari Therapeutics (AKTX) Earnings Dates & Reports
Akari Therapeutics, Plc (CLA.F)
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/31/2020
Today
3/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKTX
Employees
15
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.48 per share

Miscellaneous

Free Float
2,159,000
Market Cap
$10.45 million
Optionable
Not Optionable
Beta
1.02
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Ms. Rachelle Suzanne Jacques (Age 53)
    President, CEO & Director
    Comp: $1.38M
  • Ms. Wendy F. DiCicco CPA (Age 57)
    Interim Chief Financial Officer
  • Ms. Melissa Bradford-Klug (Age 54)
    Chief Operating Officer
  • Dr. Miles Nunn (Age 55)
    Chief Scientific Officer
  • Dr. John F. Neylan III (Age 71)
    M.D., Executive VP & Chief Medical Officer
  • Ms. Beth-Anne Lang
    Senior Vice President of Regulatory Affairs
  • Annie Mack
    Financial Controller

AKTX Stock Analysis - Frequently Asked Questions

How have AKTX shares performed in 2024?

Akari Therapeutics' stock was trading at $3.12 at the start of the year. Since then, AKTX shares have decreased by 40.7% and is now trading at $1.85.
View the best growth stocks for 2024 here
.

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 6,000 shares, a decline of 37.5% from the February 29th total of 9,600 shares. Based on an average trading volume of 9,600 shares, the short-interest ratio is presently 0.6 days. Approximately 0.1% of the shares of the stock are short sold.
View Akari Therapeutics' Short Interest
.

When is Akari Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our AKTX earnings forecast
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) released its earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Akari Therapeutics's stock reverse split on the morning of Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akari Therapeutics own?
Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Omnia Family Wealth LLC (1.55%).
View institutional ownership trends
.

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners